Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069120 · ClinicalTrials.gov registry record · Phase 3
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
A Phase 3 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT01069120: Clinical Trial Phase 3 study, sponsored by Repros Therapeutics.
NCT01069120 is a Phase 3 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 27 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01069120, a Phase 3 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
Safety and efficacy study of 25 and 50 mg doses of Proellex
Interventions
- DRUG Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Why NCT01069120 stopped before completion
NCT01069120 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Proellex is the first listed.
NCT01069120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01069120 about?
NCT01069120 is a clinical study titled "Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids". Safety and efficacy study of 25 and 50 mg doses of Proellex
What is the current status of trial NCT01069120?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2009-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT01069120?
The interventions under investigation include: Proellex (DRUG).
Who is sponsoring clinical trial NCT01069120?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01069120's enrollment target sits among peer trials
27 1936th of 2000 higher than 64 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia